Glycomed, Inc.

University of Florida Research Foundation, Incorporated

Other

Michigan State University

Kevin R Holme

Daniel E Levy

Patrick N Shaklee

Peng Cho Tang

John H Musser

Gregory Scott Schultz

Richard E Galardy

Damian Grobelny

Saeed A Abbas

David J Tyrrell

Irshad H Chaudry

Weisheng Liang

Cho Tang

Asaad Nematalia

Ole Hindsgaul

David R Bundle

Om P Srivastava

Roman Szweda

Minghui Du

Geeta Srivastava

H Rizk Hanna

Masayuki Ishihara

Frank W Barresi

A method of treating hypovolemic shock and related shock syndromes by the administration of substantially non-anticoagulant heparinoids without the hemorrhaging problems generally associated with heparin; such syndromes include degradation of the microvascular structure, immune and gastrointestinal tract dysfunction, and multiple organ failure.

Non-anticoagulant chemically modified heparinoids for treating

Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.

Process for preparing synthetic matrix metalloprotease inhibitors

Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a mammal.

Oligosaccharide glycosides having mammalian immunosuppresive and

Methods of making and using, as prophylactics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to produce compositions that are variably desulfated upto about 99% and 75% desulfated at the 2-O and 3-O positions, respectively.

Method for controlling O-desulfation of heparin

Compositions and methods of making selectively O-desulfated heparin compositions, preferably 6-O-desulfated heparin compositions, wherein the methods permit regulating the degree of 6-O-desulfation. The compositions are useful for treating various diseases, including cancer, angiogenesis, shock, ischemia reperfusion injury, inflammation, and cardiovascular diseases including restenosis.

Therapeutic methods of using O-desulfated heparin derivatives

Synthetic matrix metalloprotease inhibitors and use thereof

Methods of making and using, as prophylactics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to produce compositions that are variably desulfated upto about and 75% desulfated at the 2-O and 3-O positions, respectively.

Method for controlling O-desulfation of heparin and compositions

Glyco-amino acids and glycopeptides having three-dimensionally stable configurations are described. These glyco-amino acids and glycopeptides have glycoside functional groups, such as fucose and analogues and derivatives thereof, covalently bound to an amino acid or peptide having a free carboxylic group or sulfate group in an orientation that facilitates the binding between these groups and selectin receptors. The present glyco-amino acids and glycopeptides may be used in the treatment of selectin-mediated disorders, such as inflammation, autoimmune disease and cancer.

Selectin binding glycopeptides

Glyco-amino acids or glycopeptides that have three-dimensionally stable configuration for the presentation of functional groups, fucose, or an analogue or derivative thereof, covalently linked to an amino acid or peptide with a free carboxylic acid group, that facilitate binding between those groups and receptors on selectins, represented by the general structural formula I.

Methods of making and using, as prophylatics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to produce compositions that are variably desulfated including about 99% and 75% desulfated at the 2-O and 3-O positions, respectively.

Method for controlling o-desulfation of heparin and compositions

Growing community of inventors

Alameda, CA, United States of America

Kevin R Holme